SecBot SecBot

MIRA

MIRA PHARMACEUTICALS, INC.
Nasdaq· Pharmaceutical Preparations· Inc. FL· CIK 0001904286 Biotech & Drug Discovery
$0.5330 −0.09 (−14.03%)
Oct 26 4:00 PM ET · prev $0.6200
Market cap
$26.4M
Nano cap
Consensus
Buy
86% Buy or better · 7 analysts
Median target
$3.50
+557% · range $3.50–3.50
Next earnings
Nov 11
in 15 days · EPS est. −$0.03
1 year
−68.1%
from $1.67 · Oct 27
30 days
−41.0%
from $0.9030
52-week range
$0.5330–1.70
at the low
Avg volume 20D
128.2K
Oct 1 spike 667.7K
Short interest
🔒 Subscribers only
Insider net
$0
no open-market trades · 12 mo
New fund stakes
0
Q2 2026 13F · 0 exits
Filing reports
11
analyzed by SecBot
SecBot read BULLISH 6 reports · 90 days
Balance 0 bearish · 2 bullish · 4 neutral oldest → newest, height = score
Avg score ·High conf. 3/6 ·Next Earnings date, Nov 11, 2026
Strongest BULLISH MIRA Pharmaceuticals reported positive preclinical results for MIRA-55, an oral synthetic cannabinoid analog…
All reports →

Price

Daily candles with volume. Pins mark insider trades, rating changes, 13F stakes, reports, catalysts and short-interest jumps.

Signal stack

Where each data set points today.

  • InsidersNO TRADES

    No open-market buys or sells in 12 months. Recent filings are awards, exercises and tax withholding.

  • InstitutionsMIXED

    Q2 2026: 2 added (0 new), 4 trimmed or exited.

  • AnalystsBULLISH

    6 of 7 rate it Buy or better. Every target is above the price.

  • TrendDOWNTREND

    29% below its 50-day average. New closing low $0.5330 on Oct 26.

Who's buying

13F· Q2 2026
0
new positions
0
exits
FundMoveSharesValue
BlackRock, Inc.DOUBLED244,622$231.5K
COMMONWEALTH EQUITY SERVICES, LLCADD53,189$50.3K
SUSQUEHANNA INTERNATIONAL GROUP, LLPTRIM18,566$17.6K
UBS Group AGTRIM1,772$1.7K
CITIGROUP INCTRIM1,207$1.1K
Steward Partners Investment Advisory, LLCTRIM1,000$947.00
UBS Group AGDOUBLED6,456$6.9K
VANGUARD GROUP INCDOUBLED660,497$997.4K

Quarterly 13F filings are due 45 days after each quarter ends.

The Street

7 analysts
Buy 86% rate it Buy or better
Strong Buy2Buy4Hold1Sell0Strong Sell0
12-month targets · 1 analysts

Price is below the lowest target. Median implies +557%.Targets as of Oct 27, 2026.

Recent actions
DateFirmActionRating
Sep 17, 2026Maxim Group
INITIATE
INITIATEBuy

Insider ledger

Form 4
$0
open-market buys or sells · 12 mo
DateInsiderTypeValue
Jun 12, 2026
Del Giudice Matthew Paul
Director
AWARD50,000 sh
Jun 12, 2026
Whalen Matthew Pratt
Director
AWARD50,000 sh
Jun 12, 2026
MacPherson Edward Clouston
Director
AWARD50,000 sh
Jun 12, 2026
Shekhat Denil Nanji
Director
AWARD50,000 sh
Mar 30, 2026
Aminov Erez
Chief Executive Officer
AWARD83,500 sh

Earnings setup

Estimates
Nov 11
reports in 15 days
−$0.03
EPS estimate, this quarter
Current-quarter EPS estimate
PeriodEPS est.Range30D rev.Revenue
Current Q-$0.03-$0.03–-$0.03—$0.00
Next Q-$0.03-$0.03–-$0.03—$0.00
Current FY-$0.12-$0.12–-$0.12—$0.00
Next FY-$0.16-$0.16–-$0.16—$0.00

Short side

FINRA· Oct 15, 2026
🔒 Subscribers only
shares short
Recent activity
The latest filings, insider trades, analyst actions, press and options flow — newest first.
Oct 22, 2026 SEC
MIRA Pharmaceuticals reported positive preclinical results for MIRA-55, an oral synthetic cannabinoid analog for…
8-K — Impact 5/10
Oct 22, 2026 Press
MIRA Pharmaceuticals announced positive preclinical results for oral MIRA-55 in a 21-day chronic inflammatory pain…
Impact 5/10
Oct 22, 2026 FDA
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
MIRA-55 demonstrated significant pain relief comparable to Celebrex in a 21-day preclinical study of
Sep 17, 2026 SEC
MIRA Pharmaceuticals announced that its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral neuropathy…
8-K — Impact 4/10
Sep 17, 2026 Press
MIRA Pharmaceuticals announced submission of its Phase 2a protocol for Ketamir-2 in chemotherapy-induced peripheral…
Impact 3/10
Sep 1, 2026 SEC
MIRA Pharmaceuticals announced positive results from 7-day dose-range finding toxicology and toxicokinetic studies of…
8-K — Impact 4/10
Jun 30, 2026 Inst.
BlackRock, Inc. — DOUBLED
244,622 shares ($231.5K)
Jun 30, 2026 Inst.
COMMONWEALTH EQUITY SERVICES, LLC — ADD
53,189 shares ($50.3K)
Catalysts
Scheduled dates and disclosed events: earnings, FDA and trial readouts, halts, press releases. Colored dot = impact.
Upcoming
Nov 11, 2026
Earnings date
MIRA Q3 2026 Earnings Scheduled — 2026-11-11
Recent
Oct 22, 2026
FDA
MIRA Pharmaceuticals Reports MIRA-55 Demonstrated Significant Pain Relief Comparable to Celebrex in Chronic Inflammatory Pain Study
MIRA-55 demonstrated significant pain relief comparable to Celebrex in a 21-day preclinical study of chronic inflammatory pain....
Sep 17, 2026
FDA
MIRA Pharmaceuticals Advances Ketamir-2 to Phase 2a in Chemotherapy-Induced Peripheral Neuropathy (CIPN) Following FDA Review
Following FDA review and comments, MIRA submitted its Ketamir-2 Phase 2a CIPN protocol for IRB review at a leading cancer research institution.
Aug 12, 2026
Earnings date
MIRA Q2 2026 Earnings Scheduled — 2026-08-12
Aug 4, 2026
Listing
Listing Status: MIRA — Deficient (was Normal)
MIRA Pharmaceuticals, Inc. - Common Stock | Nasdaq Financial Status Indicator N → D
May 12, 2026
Earnings date
MIRA Q1 2026 Earnings Scheduled — 2026-05-12

SecBot reports

11 filings · 2 press releases · 3 bullish · 0 bearish · 8 neutral
All MIRA filing & press-release reports (13)